Date: 2015-12-03
Type of information: Collaboration agreement
Compound: manufacturing system for engineered T cell therapy
Company: GE Global Research (USA - NY) Kite Pharma (USA - CA)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On December 3, 2015, Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, and GE Global Research, the centralized research and development hub for GE , announced that they have formed a strategic research collaboration to develop a next-generation, functionally integrated and automated manufacturing system for engineered T cell therapy. Kite and GE Global Research aim to change the paradigm of engineered T cell therapy manufacturing by accelerating the development of automation technologies that have the potential to reduce cost, improve speed, and minimize variability. As a result, automated manufacturing technologies could enable more widespread availability of engineered T cell therapies. This collaboration brings together complementary capabilities from each company, including Kite\'s scientific leadership in T cell biology and manufacturing and GE Global Research\'s deep expertise in the design and development of innovative manufacturing applications for the biopharmaceutical industry. Under the terms of the agreement, Kite and GE Global Research will each contribute resources and relevant expertise to the partnership. Further terms of the agreement are not being disclosed.
Financial terms:
Latest news:
